Medical Advocates
Saquinavir (Fortovase/Invirase)
 
Conference Citations
 
17th CROI
Ninth Int. Congress on Drug Therapy in HIV Infection
4th IAS Conference
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
7th International Workshop on Clinical Pharm of HIV
13th CROI
3rd IAS Conference
 Archived Conferences


 
Saquinavir Main Page Main New/Newsworthy Home Page
Last Update:  January 26, 2015
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 Perinatal data are in the Perinatal Data Page.  Pediatric data are in the Pediatric Data Page
17th Conference on Retroviruses and
Opportunistic Infections
Ninth International Congress on Drug Therapy in HIV Infection
 
  • L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)
     Vachta J, Wiesmann F, Braun P, et al
    Abstract
4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention
  • NEWS RELEASE
     New Data Suggest Boosted Invirase Has Similar Efficacy to Boosted Lopinavir in HIV Patients at 24 Weeks
    Roche
    July 20, 2007
  • Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD as
    initial therapy in HIV-1 infected patients: the Gemini Study
    Raffi F, Ward D, Ruxrungtham K, et al
     Abstract
  • HIV-1 protease mutation L76V enhances susceptibility to atazanavir and saquinavir in multidrug-
    resistant HIV-1 infected patients
         Braun P, Wiesmann F, Walter H, et al
     Abstract
14th Conference on Retroviruses and
Opportunistic Infections
8th Int Congress on Drug Therapy in HIV Infection
 
  • Saquinavir in double protease inhibitor regimens boosted with ritonavir (r) results of the AROMA-
    cohort: comparison of saquinavir/atazanavir/r versus saquinavir/lopinavir/r
         A Baumgarten
    Abstract
  • Ritonavir boosted saquinavir once daily an Indian experience
         S Kadappa, BRS Rao, G V Mallesh, et al
     Abstract
  • Switching to saquinavir 500mg-based regimens maintains antiretroviral efficacy
         T Mahungu, J Ballinger, L Swaden, et al
         Abstract
  • The Rainbow Cohort: successful initiation/switch with/from the new saquinavir 500mg formulation
    first results from Germany
     H Knechten, T Lutz, G Knecht, A Haber. et al
     Abstract
  • Effect of boosted saquinavir on the pharmacokinetics and pharmacodynamics of racemic
    methadone in opiate-dependent patients on stable methadone maintenance therapy
         C Jamois, M Riek, A Patel, et al
     Abstract
  • Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD
    in ARV-nave HIV-1 infected patients: GEMINI Study
         J Slim, A Avihingsanon, K Ruxrungtham, et al
     Abstract
  • Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and
    500mg film-coated tablet (FCT) formulations of saquinavir
         L Dickinson, D Back, A Winston, et al
     Abstract
XVI International AIDS Conference
 
7th International Workshop on Clinical Pharmacology of
HIV Therapy
13th Conference on Retroviruses and
Opportunistic Infections
3rd IAS Conference
 
  • Resistance mutations in ARV-naïve patients treated with ritonavir-boosted saquinavir
     J Ananworanich, K Ruxrungtham, S Sirivichayakul, et al 
    Abstract
  • Reduced rates of viral load suppression at six to 12 months by saquinavir and nelfinavir are
    not solely explained by reduced adherence to therapy.
    Moore D., Hogg R., Yip B., et al
         Abstract
  • Hepatocellular toxicity in patients with HIV/TB co-infection receiving Rifampicin in combination
    with Saquinavir and Ritonavir
    Duran A., Lourtau L., Toibaro J., et al
         Abstract
Saquinavir Main Page Main New/Newsworthy Home Page

Saquinavir  Conference Reports, Abstracts, and Posters